3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Kymera Therapeutics is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Sezary syndrome | a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation | Des.TrialAppr. |
| acute myeloid leukemia | A ligand binding moiety to MDM2, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to MDM2 degradation. | Des.TrialAppr. |
| mature T-cell and NK-cell non-Hodgkin lymphoma | a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation | Des.TrialAppr. |
| mycosis fungoides | a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation | Des.TrialAppr. |
| primary cutaneous T-cell non-Hodgkin lymphoma | a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
22
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
22
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio